Literature DB >> 25981845

Differential expression of plasma microRNA in preeclamptic patients at delivery and 1 year postpartum.

Malia Su-Qin Murphy1, Richard Cary Casselman1, Chandrakant Tayade1, Graeme Neil Smith2.   

Abstract

OBJECTIVE: Preeclampsia (PE) is a hypertensive disorder of pregnancy characterized by widespread maternal endothelial dysfunction. Although clinical signs subside following delivery, long-term risks associated with PE include hypertension, stroke, and cardiovascular disease. MicroRNAs (miRNAs) are emerging as critical regulators of biological function, and while alterations to the miRNAome have been described in the context of pregnancy and PE, the postpartum implications of PE on miRNA expression is unknown. The goal of this study was to characterize circulating miRNA profiles at the time of delivery and at 1 year postpartum for women who did and did not develop PE. STUDY
DESIGN: Using a targeted reverse transcription polymerase chain reaction approach, selected miRNAs putatively involved in the pathophysiology of PE were examined in 17 normotensive control and 13 PE maternal plasma samples at the time of delivery and 1 year postpartum. Ingenuity Pathway Analysis was used to map putative messenger RNA targets of differentially expressed miRNA to global molecular networks based on gene function.
RESULTS: Significant increases (P < .05) in 7 miRNAs with antiangiogenic, inflammatory, and apoptotic functions (miR-98-5p, miR-222-3p, miR-210-3p, miR-155-5p, miR-296-3p, miR-181a-5p, miR-29b-3p) were evident in maternal plasma at the time of severe PE compared to time-matched controls. Plasma samples from individuals who developed mild PE exhibited no changes compared to control samples for the subset of miRNAs analyzed here. Differential expression of plasma miRNA at the time of delivery for women with PE were largely resolved at 1 year postpartum, and reduced expression of only miR-221-3p (P < .05) was evident. Network analysis of putative targets of differentially regulated miRNA identified 11 interacting networks with enrichment for proteins involved in cardiovascular disease, organ system development and function, and cell signaling and interaction.
CONCLUSION: The systemic effect of PE on maternal systems is evident in the circulating miRNAome with substantial alterations in miRNA expression in women who develop severe PE. In addition we provide novel evidence of disruption to miR-221 expression 1 year postpartum following a pregnancy complicated by PE compared to normotensive time-matched controls, which may allude to persistent inflammation in these women after delivery.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular risk; microRNA; preeclampsia

Mesh:

Substances:

Year:  2015        PMID: 25981845     DOI: 10.1016/j.ajog.2015.05.013

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  22 in total

Review 1.  Maternal Circulating microRNAs and Pre-Eclampsia: Challenges for Diagnostic Potential.

Authors:  Malia S Q Murphy; Chandrakant Tayade; Graeme N Smith
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

2.  Physical activity and epigenetic biomarkers in maternal blood during pregnancy.

Authors:  Sylvia E Badon; Alyson J Littman; Kwun Chuen Gary Chan; Mahlet G Tadesse; Patricia L Stapleton; Theo K Bammler; Tanya K Sorensen; Michelle A Williams; Daniel A Enquobahrie
Journal:  Epigenomics       Date:  2018-10-16       Impact factor: 4.778

3.  Trimester-specific plasma exosome microRNA expression profiles in preeclampsia.

Authors:  Eric Devor; Donna Santillan; Sabrina Scroggins; Akshaya Warrier; Mark Santillan
Journal:  J Matern Fetal Neonatal Med       Date:  2019-01-30

4.  Expression and role of microRNA 18b and hypoxia inducible factor-1α in placental tissues of preeclampsia patients.

Authors:  Shenglan Wang; Xuemei Wang; Zhanping Weng; Shuping Zhang; Hui Ning; Baolai Li
Journal:  Exp Ther Med       Date:  2017-08-30       Impact factor: 2.447

Review 5.  Recent research progress of microRNAs in hypertension pathogenesis, with a focus on the roles of miRNAs in pulmonary arterial hypertension.

Authors:  Chenggui Miao; Jun Chang; Guoxue Zhang
Journal:  Mol Biol Rep       Date:  2018-10-08       Impact factor: 2.316

6.  High-throughput miRNA sequencing of the human placenta: expression throughout gestation.

Authors:  Tania L Gonzalez; Laura E Eisman; Nikhil V Joshi; Amy E Flowers; Di Wu; Yizhou Wang; Chintda Santiskulvong; Jie Tang; Rae A Buttle; Erica Sauro; Ekaterina L Clark; Rosemarie DiPentino; Caroline A Jefferies; Jessica L Chan; Yayu Lin; Yazhen Zhu; Yalda Afshar; Hsian-Rong Tseng; Kent Taylor; John Williams; Margareta D Pisarska
Journal:  Epigenomics       Date:  2021-05-25       Impact factor: 4.778

Review 7.  Combined Screening for Early Detection of Pre-Eclampsia.

Authors:  Hee Jin Park; Sung Shin Shim; Dong Hyun Cha
Journal:  Int J Mol Sci       Date:  2015-08-04       Impact factor: 5.923

Review 8.  Systematic Review of Micro-RNA Expression in Pre-Eclampsia Identifies a Number of Common Pathways Associated with the Disease.

Authors:  Adam M Sheikh; Heather Yvonne Small; Gemma Currie; Christian Delles
Journal:  PLoS One       Date:  2016-08-16       Impact factor: 3.240

9.  miRNAs and sports: tracking training status and potentially confounding diagnoses.

Authors:  Anne Hecksteden; Petra Leidinger; Christina Backes; Stefanie Rheinheimer; Mark Pfeiffer; Alexander Ferrauti; Michael Kellmann; Farbod Sedaghat-Hamedani; Benjamin Meder; Eckart Meese; Tim Meyer; Andreas Keller
Journal:  J Transl Med       Date:  2016-07-26       Impact factor: 5.531

Review 10.  Role of Extracellular Vesicles and microRNAs on Dysfunctional Angiogenesis during Preeclamptic Pregnancies.

Authors:  Carlos A Escudero; Kurt Herlitz; Felipe Troncoso; Jesenia Acurio; Claudio Aguayo; James M Roberts; Grace Truong; Gregory Duncombe; Gregory Rice; Carlos Salomon
Journal:  Front Physiol       Date:  2016-03-18       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.